Loading…

Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage

Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1). Twenty neonatal pigs (weight 1.8 to 2.8 kg...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2000-02, Vol.101 (5), p.541-546
Main Authors: CHAI, P. J, NASSAR, R, OAKELEY, A. E, CRAIG, D. M, QUICK, G. JR, JAGGERS, J, SANDERS, S. P, UNGERLEIDER, R. M, ANDERSON, P. A. W
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63
cites cdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63
container_end_page 546
container_issue 5
container_start_page 541
container_title Circulation (New York, N.Y.)
container_volume 101
creator CHAI, P. J
NASSAR, R
OAKELEY, A. E
CRAIG, D. M
QUICK, G. JR
JAGGERS, J
SANDERS, S. P
UNGERLEIDER, R. M
ANDERSON, P. A. W
description Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1). Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023). sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.
doi_str_mv 10.1161/01.CIR.101.5.541
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70890379</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>53910976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</originalsourceid><addsrcrecordid>eNpdkd1rFDEUxYNY7Lb13ScJIj511iSTj51HWbQWCoIfzyGT3NQp-RiTGWT_e1N3QenT5cDvHO7hIPSKki2lkr4ndLu__bql7Yqt4PQZ2lDBeMdFPzxHG0LI0KmesXN0UetDk7JX4gU6p0RKpgTboN_fcljHANjmOAeIkBZcwMK85NJRPJe8gF0q_gmmLNc4rOn-GpvksDXFTcbieMh-Cuav0a_JLlNO2Jccj0Se1xBzMuWAx8NsasXORHMPV-jMm1Dh5eleoh-fPn7ff-7uvtzc7j_cdZb3fOkGT0BJwuzo1cA9oVKQnR0Vp44CF2CocOCElcwwEJyM3hLliBrNuAPlZH-J3h1zW5NfK9RFx6laCMEkyGvViuwG0quhgW-egA95Lan9phllSu5aeoPIEbIl11rA67lMsZXTlOjHRTShui3SJNVCt0Wa5fUpdx0juP8Mxwka8PYEmGpN8MUkO9V_HJP9MLD-Dy4UlSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212768540</pqid></control><display><type>article</type><title>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</title><source>EZB Electronic Journals Library</source><creator>CHAI, P. J ; NASSAR, R ; OAKELEY, A. E ; CRAIG, D. M ; QUICK, G. JR ; JAGGERS, J ; SANDERS, S. P ; UNGERLEIDER, R. M ; ANDERSON, P. A. W</creator><creatorcontrib>CHAI, P. J ; NASSAR, R ; OAKELEY, A. E ; CRAIG, D. M ; QUICK, G. JR ; JAGGERS, J ; SANDERS, S. P ; UNGERLEIDER, R. M ; ANDERSON, P. A. W</creatorcontrib><description>Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1). Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023). sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.101.5.541</identifier><identifier>PMID: 10662752</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Actin Cytoskeleton - chemistry ; Actin Cytoskeleton - drug effects ; Actin Cytoskeleton - physiology ; Anesthesia ; Anesthesia depending on type of surgery ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Biological and medical sciences ; Blood Pressure - drug effects ; Calcium - metabolism ; Cardiopulmonary Bypass - adverse effects ; Heart Diseases - etiology ; Heart Diseases - physiopathology ; Heart Diseases - prevention &amp; control ; Heart Function Tests ; Lung Diseases - etiology ; Lung Diseases - physiopathology ; Lung Diseases - prevention &amp; control ; Medical sciences ; Oxygen - metabolism ; Postoperative Complications - prevention &amp; control ; Protective Agents - therapeutic use ; Protein Conformation ; Receptors, Complement - therapeutic use ; Respiratory Function Tests ; Swine ; Thoracic and cardiovascular surgery. Cardiopulmonary bypass ; Time Factors</subject><ispartof>Circulation (New York, N.Y.), 2000-02, Vol.101 (5), p.541-546</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Feb 8, 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</citedby><cites>FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1263992$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10662752$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHAI, P. J</creatorcontrib><creatorcontrib>NASSAR, R</creatorcontrib><creatorcontrib>OAKELEY, A. E</creatorcontrib><creatorcontrib>CRAIG, D. M</creatorcontrib><creatorcontrib>QUICK, G. JR</creatorcontrib><creatorcontrib>JAGGERS, J</creatorcontrib><creatorcontrib>SANDERS, S. P</creatorcontrib><creatorcontrib>UNGERLEIDER, R. M</creatorcontrib><creatorcontrib>ANDERSON, P. A. W</creatorcontrib><title>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1). Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023). sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.</description><subject>Actin Cytoskeleton - chemistry</subject><subject>Actin Cytoskeleton - drug effects</subject><subject>Actin Cytoskeleton - physiology</subject><subject>Anesthesia</subject><subject>Anesthesia depending on type of surgery</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium - metabolism</subject><subject>Cardiopulmonary Bypass - adverse effects</subject><subject>Heart Diseases - etiology</subject><subject>Heart Diseases - physiopathology</subject><subject>Heart Diseases - prevention &amp; control</subject><subject>Heart Function Tests</subject><subject>Lung Diseases - etiology</subject><subject>Lung Diseases - physiopathology</subject><subject>Lung Diseases - prevention &amp; control</subject><subject>Medical sciences</subject><subject>Oxygen - metabolism</subject><subject>Postoperative Complications - prevention &amp; control</subject><subject>Protective Agents - therapeutic use</subject><subject>Protein Conformation</subject><subject>Receptors, Complement - therapeutic use</subject><subject>Respiratory Function Tests</subject><subject>Swine</subject><subject>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</subject><subject>Time Factors</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNpdkd1rFDEUxYNY7Lb13ScJIj511iSTj51HWbQWCoIfzyGT3NQp-RiTGWT_e1N3QenT5cDvHO7hIPSKki2lkr4ndLu__bql7Yqt4PQZ2lDBeMdFPzxHG0LI0KmesXN0UetDk7JX4gU6p0RKpgTboN_fcljHANjmOAeIkBZcwMK85NJRPJe8gF0q_gmmLNc4rOn-GpvksDXFTcbieMh-Cuav0a_JLlNO2Jccj0Se1xBzMuWAx8NsasXORHMPV-jMm1Dh5eleoh-fPn7ff-7uvtzc7j_cdZb3fOkGT0BJwuzo1cA9oVKQnR0Vp44CF2CocOCElcwwEJyM3hLliBrNuAPlZH-J3h1zW5NfK9RFx6laCMEkyGvViuwG0quhgW-egA95Lan9phllSu5aeoPIEbIl11rA67lMsZXTlOjHRTShui3SJNVCt0Wa5fUpdx0juP8Mxwka8PYEmGpN8MUkO9V_HJP9MLD-Dy4UlSg</recordid><startdate>20000208</startdate><enddate>20000208</enddate><creator>CHAI, P. J</creator><creator>NASSAR, R</creator><creator>OAKELEY, A. E</creator><creator>CRAIG, D. M</creator><creator>QUICK, G. JR</creator><creator>JAGGERS, J</creator><creator>SANDERS, S. P</creator><creator>UNGERLEIDER, R. M</creator><creator>ANDERSON, P. A. W</creator><general>Lippincott Williams &amp; Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20000208</creationdate><title>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</title><author>CHAI, P. J ; NASSAR, R ; OAKELEY, A. E ; CRAIG, D. M ; QUICK, G. JR ; JAGGERS, J ; SANDERS, S. P ; UNGERLEIDER, R. M ; ANDERSON, P. A. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Actin Cytoskeleton - chemistry</topic><topic>Actin Cytoskeleton - drug effects</topic><topic>Actin Cytoskeleton - physiology</topic><topic>Anesthesia</topic><topic>Anesthesia depending on type of surgery</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium - metabolism</topic><topic>Cardiopulmonary Bypass - adverse effects</topic><topic>Heart Diseases - etiology</topic><topic>Heart Diseases - physiopathology</topic><topic>Heart Diseases - prevention &amp; control</topic><topic>Heart Function Tests</topic><topic>Lung Diseases - etiology</topic><topic>Lung Diseases - physiopathology</topic><topic>Lung Diseases - prevention &amp; control</topic><topic>Medical sciences</topic><topic>Oxygen - metabolism</topic><topic>Postoperative Complications - prevention &amp; control</topic><topic>Protective Agents - therapeutic use</topic><topic>Protein Conformation</topic><topic>Receptors, Complement - therapeutic use</topic><topic>Respiratory Function Tests</topic><topic>Swine</topic><topic>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHAI, P. J</creatorcontrib><creatorcontrib>NASSAR, R</creatorcontrib><creatorcontrib>OAKELEY, A. E</creatorcontrib><creatorcontrib>CRAIG, D. M</creatorcontrib><creatorcontrib>QUICK, G. JR</creatorcontrib><creatorcontrib>JAGGERS, J</creatorcontrib><creatorcontrib>SANDERS, S. P</creatorcontrib><creatorcontrib>UNGERLEIDER, R. M</creatorcontrib><creatorcontrib>ANDERSON, P. A. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHAI, P. J</au><au>NASSAR, R</au><au>OAKELEY, A. E</au><au>CRAIG, D. M</au><au>QUICK, G. JR</au><au>JAGGERS, J</au><au>SANDERS, S. P</au><au>UNGERLEIDER, R. M</au><au>ANDERSON, P. A. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2000-02-08</date><risdate>2000</risdate><volume>101</volume><issue>5</issue><spage>541</spage><epage>546</epage><pages>541-546</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1). Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023). sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>10662752</pmid><doi>10.1161/01.CIR.101.5.541</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-7322
ispartof Circulation (New York, N.Y.), 2000-02, Vol.101 (5), p.541-546
issn 0009-7322
1524-4539
language eng
recordid cdi_proquest_miscellaneous_70890379
source EZB Electronic Journals Library
subjects Actin Cytoskeleton - chemistry
Actin Cytoskeleton - drug effects
Actin Cytoskeleton - physiology
Anesthesia
Anesthesia depending on type of surgery
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Animals
Biological and medical sciences
Blood Pressure - drug effects
Calcium - metabolism
Cardiopulmonary Bypass - adverse effects
Heart Diseases - etiology
Heart Diseases - physiopathology
Heart Diseases - prevention & control
Heart Function Tests
Lung Diseases - etiology
Lung Diseases - physiopathology
Lung Diseases - prevention & control
Medical sciences
Oxygen - metabolism
Postoperative Complications - prevention & control
Protective Agents - therapeutic use
Protein Conformation
Receptors, Complement - therapeutic use
Respiratory Function Tests
Swine
Thoracic and cardiovascular surgery. Cardiopulmonary bypass
Time Factors
title Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T18%3A17%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20complement%20receptor-1%20protects%20heart,%20lung,%20and%20cardiac%20myofilament%20function%20from%20cardiopulmonary%20bypass%20damage&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=CHAI,%20P.%20J&rft.date=2000-02-08&rft.volume=101&rft.issue=5&rft.spage=541&rft.epage=546&rft.pages=541-546&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.101.5.541&rft_dat=%3Cproquest_cross%3E53910976%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c434t-9f0e7602cbf794f016508cb741d1e45ea15ded5c62a2e540bfc07d07bab8e7d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=212768540&rft_id=info:pmid/10662752&rfr_iscdi=true